Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults

European Journal of Clinical Pharmacology

Volumn 56, Issue 12, 2001, Pages 897-903

  Isaacsohn, J ^a   Zinny, M ^b   Mazzu, A ^c   Lettieri, J ^c   Heller, A H ^c  

^a Metabolic and Atherosclerosis Research Center   (United States)

^b Medical and Technical Research Associates Inc   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

Cerivastatin; HMG CoA reductase inhibitor; Statins

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; AGE; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIDINES; SEX FACTORS;

EID: 0034464614     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000225     Document Type: Article

References (19)

1. Walsh JM, Grady D (1995) Treatment of hyperlipidemia in women. JAMA 274:1152-1158
2. Kannel WB, Vokonas PS (1992) Demographics of the prevalence, incidence, and management of coronary heart disease in the elderly and in women. Ann Epidemiol 2:5-14
3. Holme I (1995) Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 76:10C-17C
4. Stein EA (1994) Drug and alternative therapies for hyperlipidemia. Atherosclerosis 108 (Suppl):S105-S116
5. (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344:1383-1389
6. Kjekshus J, Pedersen TR (1995) Reducing the risk of coronary events: evidence from the Scandinavian simvastatin survival study (4S). Am J Cardiol 76:64C-68C
7. Sacks FM, Pfeffer MA. Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L. Warnica JW et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335: 1001-1009
8. (1998) The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357
9. Downs JR. Clearfield M, Weis S. Whitney E, Shapiro DR. Beere PA, Langendorfer A, Stein EA et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622
10. Sinzinger H, Pirich C (1994) The red-lip study pravastatin in primary isolated hypercholesterolemia - an open, prospective, multicenter trial. Wien Klin Wochenschr 106:721-727
11. Clifton PM, Noakes M, Nestel PJ (1994) Gender and diet interactions with simvastatin treatment. Atherosclerosis 110: 25-33
12. Stein E (1998) Cerivastatin in primary hyperlipidemia - a multicenter analysis of efficacy and safety. Atherosclerosis 139 (Suppl 1):S15-S22
13. Stein E, Isaacsohn J, Stoltz R. Mazzu A, Liu MC, Lane C, Heller AH (1999) Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Am J Cardiol 83:1433-1436
14. Stein E, Sprecher DL, Allenby KS, Tosiello R, Whalen E, Ripa SR, the Cerivastatin Study Group (1997) Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg/day in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Therapeut 2:7-16
15. Ose L. Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B (2000) Cerivastatin gender effect: sub-analyses of results from a multinational, randomised, double-blind study. Cerivastatin Study Group. Curr Med Res Opin 16:80-87
16. Krol GJ, Beck GW, Ritter W, Lettieri JT, Ness GC, Lopez D, Heller AH (1994) Determination of rivastatin levels in plasma samples by HPLC and enzyme inhibition assays. In: Reid R, Wilson ID (eds) Biofluid and tissue analysis for drugs, including hypolipidaemics. Royal Society of Chemistry, Cambridge, pp 147-156
17. Cheng H, Rogers JD, Sweany AE, Dobrinska MR, Stein EA. Tate AC, Amin RD, Quan H (1992) Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutarylcoenzyme a (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 9:1629-1633
18. Pan HY, Waclawski AP, Funke PT, Whigan D (1993) Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 27:1029-1033
19. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR (1996) Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 36:242-246